Advanced search
1 file | 113.67 KB Add to list

Orlistat treatment is safe in overweight and obese liver transplant recipients: a prospective, open label trial

(2006) TRANSPLANT INTERNATIONAL. 19(12). p.1000-1005
Author
Organization
Abstract
Obesity is a frequent complication following liver transplantation and is insufficiently responsive to dietary and life style advice. We studied the safety of orlistat treatment in obese and overweight liver transplant recipients (n = 15) on a stable tacrolimus-based immunosuppressive regimen. For safety reasons, the treatment period was restricted (6 months 120 mg t.i.d., 3 months 120 mg daily). Three patients dropped out, tacrolimus dose was adjusted in six of 12 remaining patients (dose reduction in 4, increase in 2, P = N.S.). All dose adjustments occurred during the 6 months of orlistat 120 mg t.i.d. therapy. No drug intolerance, adverse events or episodes of rejection occurred during the study. Efficacy of orlistat treatment in this population could not be shown, because a formal control population was not included in this safety trial. Moreover, only a significant decrease of waist circumference (P < 0.01 versus start of the study), but not of weight or body mass index, was achieved in the treated group. Orlistat treatment is well tolerated in liver transplant recipients and can be started safely, provided immunosuppressive drug levels and dietary adherence are closely monitored.
Keywords
drug interaction, cyclosporin, nonalcoholic fatty liver disease, tacrolimus, weight loss, BLOOD CYCLOSPORINE CONCENTRATION, RISK-FACTORS, WEIGHT-LOSS, REDUCTION, FAILURE, PATIENT

Downloads

  • (...).pdf
    • full text
    • |
    • UGent only
    • |
    • PDF
    • |
    • 113.67 KB

Citation

Please use this url to cite or link to this publication:

MLA
Cassiman, David, Mieke Roelants, Gerda Vandenplas, et al. “Orlistat Treatment Is Safe in Overweight and Obese Liver Transplant Recipients: a Prospective, Open Label Trial.” TRANSPLANT INTERNATIONAL 19.12 (2006): 1000–1005. Print.
APA
Cassiman, D., Roelants, M., Vandenplas, G., Van der Merwe, S. W., Mertens, A., Libbrecht, L., Verslype, C., et al. (2006). Orlistat treatment is safe in overweight and obese liver transplant recipients: a prospective, open label trial. TRANSPLANT INTERNATIONAL, 19(12), 1000–1005.
Chicago author-date
Cassiman, David, Mieke Roelants, Gerda Vandenplas, Schalk W Van der Merwe, Ann Mertens, Louis Libbrecht, Chris Verslype, et al. 2006. “Orlistat Treatment Is Safe in Overweight and Obese Liver Transplant Recipients: a Prospective, Open Label Trial.” Transplant International 19 (12): 1000–1005.
Chicago author-date (all authors)
Cassiman, David, Mieke Roelants, Gerda Vandenplas, Schalk W Van der Merwe, Ann Mertens, Louis Libbrecht, Chris Verslype, Johan Fevery, Raymond Aerts, Jacques Pirenne, Erik Muls, and Frederik Nevens. 2006. “Orlistat Treatment Is Safe in Overweight and Obese Liver Transplant Recipients: a Prospective, Open Label Trial.” Transplant International 19 (12): 1000–1005.
Vancouver
1.
Cassiman D, Roelants M, Vandenplas G, Van der Merwe SW, Mertens A, Libbrecht L, et al. Orlistat treatment is safe in overweight and obese liver transplant recipients: a prospective, open label trial. TRANSPLANT INTERNATIONAL. 2006;19(12):1000–5.
IEEE
[1]
D. Cassiman et al., “Orlistat treatment is safe in overweight and obese liver transplant recipients: a prospective, open label trial,” TRANSPLANT INTERNATIONAL, vol. 19, no. 12, pp. 1000–1005, 2006.
@article{3183576,
  abstract     = {Obesity is a frequent complication following liver transplantation and is insufficiently responsive to dietary and life style advice. We studied the safety of orlistat treatment in obese and overweight liver transplant recipients (n = 15) on a stable tacrolimus-based immunosuppressive regimen. For safety reasons, the treatment period was restricted (6 months 120 mg t.i.d., 3 months 120 mg daily). Three patients dropped out, tacrolimus dose was adjusted in six of 12 remaining patients (dose reduction in 4, increase in 2, P = N.S.). All dose adjustments occurred during the 6 months of orlistat 120 mg t.i.d. therapy. No drug intolerance, adverse events or episodes of rejection occurred during the study. Efficacy of orlistat treatment in this population could not be shown, because a formal control population was not included in this safety trial. Moreover, only a significant decrease of waist circumference (P < 0.01 versus start of the study), but not of weight or body mass index, was achieved in the treated group. Orlistat treatment is well tolerated in liver transplant recipients and can be started safely, provided immunosuppressive drug levels and dietary adherence are closely monitored.},
  author       = {Cassiman, David and Roelants, Mieke and Vandenplas, Gerda and Van der Merwe, Schalk W and Mertens, Ann and Libbrecht, Louis and Verslype, Chris and Fevery, Johan and Aerts, Raymond and Pirenne, Jacques and Muls, Erik and Nevens, Frederik},
  issn         = {0934-0874},
  journal      = {TRANSPLANT INTERNATIONAL},
  keywords     = {drug interaction,cyclosporin,nonalcoholic fatty liver disease,tacrolimus,weight loss,BLOOD CYCLOSPORINE CONCENTRATION,RISK-FACTORS,WEIGHT-LOSS,REDUCTION,FAILURE,PATIENT},
  language     = {eng},
  number       = {12},
  pages        = {1000--1005},
  title        = {Orlistat treatment is safe in overweight and obese liver transplant recipients: a prospective, open label trial},
  url          = {http://dx.doi.org/10.1111/j.1432-2277.2006.00379.x},
  volume       = {19},
  year         = {2006},
}

Altmetric
View in Altmetric
Web of Science
Times cited: